Barclays Upgrades uniQure N.V. to 'Buy' with $65 Price Target
Barclays has raised its rating on uniQure N.V. to 'buy' and set a price target of $65.
Key Points
- Barclays upgraded uniQure N.V. to a 'buy' rating with a price target of $65 on June 18, 2026.
- Shares of NasdaqGS:QURE traded at $48.16, with a market cap of $3.04 billion and a 52-week high of $71.50.
- Insider transactions include sales by Robert Gut and Jeannette Potts, and a planned sale by Madhavan Balachandran.
Barclays has upgraded its rating on uniQure N.V. (NasdaqGS:QURE) to 'buy', setting a new price target of $65. This change was announced on June 18, 2026, as analyst Eliana Merle expressed confidence in the company's prospects.
Other Institutional Activity in uniQure
Several other institutional investors have adjusted their positions in uniQure. AVORO Capital Advisors LLC trimmed its holdings by 190,405 shares, bringing its total to approximately 5.96 million shares valued at about $97.4 million. On the other hand, Aberdeen Group PLC increased its stake by 1.63 million shares, ending with 5.31 million shares worth around $86.8 million. Two Sigma Investments, LP also boosted its holdings significantly by 1.22 million shares, totaling 2.68 million shares valued at $43.8 million.
uniQure Stock Snapshot
Shares of uniQure N.V. traded at $48.16 on the NasdaqGS. The company boasts a market cap of around $3.04 billion. Despite not being profitable, as indicated by its negative forward P/E ratio, the stock has shown resilience with a 52-week high of $71.50 and a low of $8.73. Its 50-day moving average stands at $23.52, while the 200-day moving average is $27.38. The company's current ratio is a robust 10.40, with a quick ratio of 9.97, though it carries a high debt-to-equity ratio of 365.37.
Recent Earnings
In its latest earnings report, uniQure reported revenue of about $18.1 million, with a growth rate of 1.27%. However, the company has struggled with profitability, showing a return on equity of -228.24% and a net margin of 0.0%. The next earnings release is expected on July 29, 2026.
Insider Buying and Selling at uniQure N.V.
Recent insider activity at uniQure includes several transactions. On June 15, 2026, Madhavan Balachandran sold 10,000 shares, while Jeannette Potts, the Chief Legal Officer, sold 5,237 shares at an average price of $27.67. Balachandran also executed a planned sale of 10,000 shares at $27.85. Earlier on June 11, Robert Gut sold 2,726 shares at $27.06, and Rachelle Suzanne Jacques sold 1,993 shares at the same price.
Analysts Set New Price Targets
On June 18, 2026, Barclays upgraded uniQure to a 'buy' rating with a $65 price target. Goldman Sachs maintained its 'hold' rating, setting a target of $46, while Leerink Partners and RBC Capital both maintained 'buy' ratings with price targets of $70 and $65, respectively. The consensus among analysts is a 'buy', with an average target price of $38.78 based on 11 opinions.
About uniQure N.V.
uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands. It focuses on developing gene therapies for rare and serious diseases. The company's flagship product, HEMGENIX, helps hemophilia B patients manage bleeding risks. uniQure's pipeline includes AMT-130 for Huntington's disease and other gene therapy candidates targeting conditions like epilepsy and amyotrophic lateral sclerosis. Founded in 1998, the company is led by CEO Matthew Craig Kapusta.
Bottom Line
Barclays' upgrade to a 'buy' rating with a $65 target reflects optimism about uniQure's future. Investors should note that 13F filings and analyst ratings are backward-looking and might not represent current positions. As always, it's important to consider a comprehensive view of the company's financial health and market conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.